Raras
Buscar doenças, sintomas, genes...
Alteração do metabolismo e excreção de bilirrubina
ORPHA:309816CID-11 · 5C58.0DOENÇA RARA

É uma doença que afeta a forma como a bilirrubina é processada no corpo, e que é causada por uma alteração genética que a pessoa herdou.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma doença que afeta a forma como a bilirrubina é processada no corpo, e que é causada por uma alteração genética que a pessoa herdou.

Publicações científicas
2 artigos
Último publicado: 2023 Aug
Medicamentos
2 registrados
ODEVIXIBAT, MARALIXIBAT

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
ODEVIXIBATMARALIXIBAT
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
32 sintomas
🫘
Rins
19 sintomas
🩸
Sangue
12 sintomas
🧠
Neurológico
10 sintomas
🦴
Ossos e articulações
8 sintomas
📏
Crescimento
7 sintomas

+ 82 sintomas em outras categorias

Características mais comuns

Desidratação
Fibrose hepática
Hepatomegalia
Aumento da ecogenicidade hepática
Icterícia intermitente
Hipoplasia do esmalte
191sintomas
Sem dados (191)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 191 características clínicas mais associadas, ordenadas por frequência.

DesidrataçãoDehydration
Fibrose hepáticaHepatic fibrosis
HepatomegaliaHepatomegaly
Aumento da ecogenicidade hepáticaIncreased hepatic echogenicity
Icterícia intermitenteIntermittent jaundice

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico2PubMed
Últimos 10 anos83publicações
Pico201910 papers
Linha do tempo
20202015Hoje · 2026📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

19 genes identificados com associação a esta condição.

USP53Ubiquitin carboxyl-terminal hydrolase 53Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Deubiquitinase that mediates 'Lys-63'-linked deubiquitination of tight junction proteins, such as MARVELD2 and LSR, and which is involved in the survival of auditory hair cells and hearing (PubMed:32124521, PubMed:39587316). Specifically cleaves 'Lys-63'-linked polyubiquitin chains composed of at least 3 ubiquitin molecules, while it is not able to deubiquitinate substrates with shorter ubiquitin chains: recognizes ubiquitin chain in position S2 and catalyzes en bloc cleavage of polyubiquitin ch

LOCALIZAÇÃO

Cell junction, tight junction

MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 7, with or without hearing loss

An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. Some PFIC7 patients develop hearing loss in childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
202.8 TPM
Fibroblastos
63.9 TPM
Pulmão
58.7 TPM
Tecido adiposo
47.6 TPM
Aorta
45.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 7, with or without hearing loss
HGNC:HGNC:29255UniProt:Q70EK8
UTP4U3 small nucleolar RNA-associated protein 4 homologCandidate gene tested inTolerante
FUNÇÃO

Ribosome biogenesis factor. Involved in nucleolar processing of pre-18S ribosomal RNA. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted d Involved in SSU pre-rRNA proce

LOCALIZAÇÃO

Nucleus, nucleolusChromosome

VIAS BIOLÓGICAS (2)
rRNA modification in the nucleus and cytosolMajor pathway of rRNA processing in the nucleolus and cytosol
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
34.4 TPM
Testículo
33.7 TPM
Fibroblastos
31.4 TPM
Músculo esquelético
21.0 TPM
Útero
18.4 TPM
OUTRAS DOENÇAS (1)
hereditary North American Indian childhood cirrhosis
HGNC:1983UniProt:Q969X6
KIF12Kinesin-like protein KIF12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the negative regulation of fatty acid biosynthesis, probably acting as an adapter that allows ubiquitination of acetyl-CoA carboxylase 1 (ACACA) by E3 ubiquitin-protein ligase COP1, and promotes ACACA degradation (PubMed:39920308). The adapter function requires the C-terminal proline-rich domain and may be apart from the kinesin motor activity (Probable)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, cilium

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 8

An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. PFIC8 onset is in early infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
243.8 TPM
Rim - Córtex
166.0 TPM
Tireoide
80.1 TPM
Pâncreas
69.7 TPM
Fígado
21.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 8
HGNC:HGNC:21495UniProt:Q96FN5
ZFYVE19Abscission/NoCut checkpoint regulatorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key regulator of abscission step in cytokinesis: part of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage. Together with CHMP4C, required to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCleavage furrowMidbody, Midbody ring

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
29.0 TPM
Cervix Endocervix
27.0 TPM
Cérebro - Hemisfério cerebelar
24.8 TPM
Próstata
24.4 TPM
Nervo tibial
23.6 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 9
HGNC:HGNC:20758UniProt:Q96K21
SLCO1B1Solute carrier organic anion transporter family member 1B1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mediates the Na(+)-independent uptake of organic anions (PubMed:10358072, PubMed:15159445, PubMed:17412826). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-th

LOCALIZAÇÃO

Basolateral cell membraneBasal cell membrane

VIAS BIOLÓGICAS (4)
Heme degradationAtorvastatin ADMERecycling of bile acids and saltsOrganic anion transport by SLCO transporters
MECANISMO DE DOENÇA

Hyperbilirubinemia, Rotor type

An autosomal recessive form of primary conjugated hyperbilirubinemia. Affected individuals develop mild jaundice not associated with hemolysis shortly after birth or in childhood. They have delayed plasma clearance of the unconjugated anionic dye bromsulphthalein and prominent urinary excretion of coproporphyrin I. Hepatic pigmentation is normal.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
56.7 TPM
Testículo
0.2 TPM
Nervo tibial
0.1 TPM
Cervix Endocervix
0.0 TPM
Glândula salivar
0.0 TPM
OUTRAS DOENÇAS (1)
Rotor syndrome
HGNC:10959UniProt:Q9Y6L6
VPS33BVacuolar protein sorting-associated protein 33BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in vesicle-mediated protein trafficking to lysosomal compartments and in membrane docking/fusion reactions of late endosomes/lysosomes. Required for proper trafficking and targeting of the collagen-modifying enzyme lysyl hydroxylase 3 (LH3) to intracellular collagen (PubMed:28017832). Mediates phagolysosomal fusion in macrophages (PubMed:18474358). Proposed to be involved in endosomal maturation implicating VIPAS39. In epithelial cells, the VPS33B:VIPAS39 complex may play a role

LOCALIZAÇÃO

Late endosome membraneLysosome membraneEarly endosomeCytoplasmic vesicle, clathrin-coated vesicleRecycling endosome

VIAS BIOLÓGICAS (1)
SARS-CoV-2 modulates autophagy
MECANISMO DE DOENÇA

Arthrogryposis, renal dysfunction, and cholestasis 1

An autosomal recessive multisystem disorder with characteristics of congenital joint contractures, renal tubular dysfunction, neonatal cholestasis with bile duct hypoplasia and low gamma glutamyl transpeptidase activity, severe failure to thrive, ichthyosis, and a defect in platelet alpha-granule biogenesis. Most patients do not survive past the first year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
34.6 TPM
Cerebelo
32.5 TPM
Linfócitos
31.3 TPM
Skin Sun Exposed Lower leg
27.8 TPM
Útero
24.4 TPM
OUTRAS DOENÇAS (4)
keratoderma-ichthyosis-deafness syndrome, autosomal recessivecholestasis, progressive familial intrahepatic, 12arthrogryposis, renal dysfunction, and cholestasis 1arthrogryposis-renal dysfunction-cholestasis syndrome
HGNC:12712UniProt:Q9H267
ABCB4Phosphatidylcholine translocator ABCB4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. Translocation of PC makes the biliary phospholipids available for extraction into the canaliculi lumen by bile salt mixed micelles and therefore protects the biliary tree from the detergent activity o

LOCALIZAÇÃO

Cell membraneApical cell membraneMembrane raftCytoplasmCytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (2)
ABC-family proteins mediated transportPPARA activates gene expression
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 3

A disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease before adulthood. PFIC3 inheritance is autosomal recessive.

OUTRAS DOENÇAS (4)
gallbladder disease 1progressive familial intrahepatic cholestasis type 3cholestasis, intrahepatic, of pregnancy, 3intrahepatic cholestasis of pregnancy
HGNC:45UniProt:P21439
VIPAS39Spermatogenesis-defective protein 39 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Proposed to be involved in endosomal maturation implicating in part VPS33B. In epithelial cells, the VPS33B:VIPAS39 complex may play a role in the apical RAB11A-dependent recycling pathway and in the maintenance of the apical-basolateral polarity (PubMed:20190753). May play a role in lysosomal trafficking, probably via association with the core HOPS complex in a discrete population of endosomes; the functions seems to be independent of VPS33B (PubMed:19109425). May play a role in vesicular traff

LOCALIZAÇÃO

CytoplasmCytoplasmic vesicleEarly endosomeRecycling endosomeLate endosome

MECANISMO DE DOENÇA

Arthrogryposis, renal dysfunction and cholestasis syndrome 2

A multisystem disorder, characterized by neurogenic arthrogryposis multiplex congenita, renal tubular dysfunction and neonatal cholestasis with bile duct hypoplasia and low gamma glutamyl transpeptidase activity. Platelet dysfunction is common.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.7 TPM
Testículo
29.8 TPM
Ovário
27.4 TPM
Artéria tibial
25.9 TPM
Nervo tibial
25.3 TPM
OUTRAS DOENÇAS (2)
arthrogryposis, renal dysfunction, and cholestasis 2arthrogryposis-renal dysfunction-cholestasis syndrome
HGNC:20347UniProt:Q9H9C1
ABCB11Bile salt export pumpDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner (PubMed:15791618, PubMed:16332456, PubMed:18985798, PubMed:19228692, PubMed:20010382, PubMed:20398791, PubMed:22262466, PubMed:24711118, Pub

LOCALIZAÇÃO

Apical cell membraneRecycling endosome membraneEndosomeCell membrane

VIAS BIOLÓGICAS (2)
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterolRecycling of bile acids and salts
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 2

A disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease before adulthood. PFIC2 inheritance is autosomal recessive.

OUTRAS DOENÇAS (3)
progressive familial intrahepatic cholestasis type 2benign recurrent intrahepatic cholestasis type 2intrahepatic cholestasis of pregnancy
HGNC:42UniProt:O95342
PSKH1Serine/threonine-protein kinase H1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Serine/threonine protein kinase that may be involved in the regulation of pre-mRNA processing. It may phosphorylate components of nuclear splice factor compartments (SFC), such as non-snRNP splicing factors containing a serine/arginine-rich domain (SR proteins). Reversible phosphorylation of SR proteins may cause their release into the nucleoplasm and change their local concentration, thereby influencing alternative splicing

LOCALIZAÇÃO

Golgi apparatusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeNucleus speckleEndoplasmic reticulum membraneCell membraneCytoplasm

MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 13

A form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. PFIC13 is an autosomal recessive form characterized by progressive liver dysfunction and chronic renal failure often associated with unilateral renal agenesis and glomerulosclerosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
46.0 TPM
Útero
37.3 TPM
Ovário
34.7 TPM
Fallopian Tube
34.5 TPM
Esôfago - Junção
33.3 TPM
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 13
HGNC:HGNC:9529UniProt:P11801
MYO5BUnconventional myosin-VbDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation. Required in a complex with RAB11A and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Together with RAB11A participates in CFTR trafficking to the plasma membrane and TF (transferrin) recycling in nonpolarized cells. Together with RAB11A and RAB8A participates in epithelial cell polarization. Tog

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Vasopressin regulates renal water homeostasis via Aquaporins
MECANISMO DE DOENÇA

Diarrhea 2, with microvillus atrophy, with or without cholestasis

A disease characterized by onset of intractable life-threatening watery diarrhea during infancy. Two forms are recognized: early-onset microvillus inclusion disease with diarrhea beginning in the neonatal period, and late-onset, with first symptoms appearing after 3 or 4 months of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
20.9 TPM
Tireoide
20.5 TPM
Skin Sun Exposed Lower leg
20.1 TPM
Glândula salivar
18.1 TPM
Vagina
18.0 TPM
OUTRAS DOENÇAS (4)
microvillus inclusion diseasecholestasis, progressive familial intrahepatic, 10MYO5B-related progressive familial intrahepatic cholestasisprogressive familial intrahepatic cholestasis type 1
HGNC:7603UniProt:Q9ULV0
NR1H4Bile acid receptorDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response (PubMed:10334992, PubMed:10334993, PubMed:21383957, PubMed:22820415). The FXR-RXR heterodimer binds

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
Recycling of bile acids and saltsSynthesis of bile acids and bile saltsEndogenous sterolsSynthesis of bile acids and bile salts via 7alpha-hydroxycholesterolSynthesis of bile acids and bile salts via 27-hydroxycholesterol
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
39.1 TPM
Glândula adrenal
22.9 TPM
Intestino delgado
21.5 TPM
Ovário
12.9 TPM
Rim - Medula
11.2 TPM
OUTRAS DOENÇAS (2)
cholestasis, progressive familial intrahepatic, 5intrahepatic cholestasis of pregnancy
HGNC:7967UniProt:Q96RI1
ABCC2ATP-binding cassette sub-family C member 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

ATP-dependent transporter of the ATP-binding cassette (ABC) family that binds and hydrolyzes ATP to enable active transport of various substrates including many drugs, toxicants and endogenous compound across cell membranes. Transports a wide variety of conjugated organic anions such as sulfate-, glucuronide- and glutathione (GSH)-conjugates of endo- and xenobiotics substrates (PubMed:10220572, PubMed:10421658, PubMed:11500505, PubMed:16332456). Mediates hepatobiliary excretion of mono- and bis-

LOCALIZAÇÃO

Apical cell membrane

VIAS BIOLÓGICAS (5)
Heme degradationABC-family proteins mediated transportParacetamol ADMEAspirin ADMEAtorvastatin ADME
MECANISMO DE DOENÇA

Dubin-Johnson syndrome

Autosomal recessive disorder characterized by conjugated hyperbilirubinemia, an increase in the urinary excretion of coproporphyrin isomer I, deposition of melanin-like pigment in hepatocytes, and prolonged retention of sulfobromophthalein, but otherwise normal liver function.

OUTRAS DOENÇAS (1)
Dubin-Johnson syndrome
HGNC:53UniProt:Q92887
UGT1A1UDP-glucuronosyltransferase 1A1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15472229, PubMed:18004206, PubMed:18004212, PubMed:18719240, PubMed:19830808, PubMed:23288867, PubMed:15231852, PubMed:21422672, PubMed:38211441). Essential for the elimination and detoxification of drugs, xenobiot

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasm, perinuclear region

VIAS BIOLÓGICAS (4)
GlucuronidationHeme degradationAspirin ADMEParacetamol ADME
MECANISMO DE DOENÇA

Gilbert syndrome

Occurs as a consequence of reduced bilirubin transferase activity and is often detected in young adults with vague non-specific complaints.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
22.6 TPM
Esôfago - Mucosa
4.2 TPM
Intestino delgado
2.3 TPM
Rim - Córtex
2.2 TPM
Cólon transverso
1.4 TPM
OUTRAS DOENÇAS (5)
Gilbert syndromeobsolete bilirubin, serum level of, quantitative trait locus 1Crigler-Najjar syndrome type 2transient familial neonatal hyperbilirubinemia
HGNC:12530UniProt:P22309
SLCO1B3Solute carrier organic anion transporter family member 1B3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mediates the Na(+)-independent uptake of organic anions (PubMed:10779507, PubMed:15159445, PubMed:17412826). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (17-beta-glucuronosyl estradiol, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate), as well as eicosanoid leukotriene C4, prostaglandin E2 and L-thyroxine (T4) (PubMed:10779507, PubMed:11159893, PubMed:12568656, PubMed:15159445, PubMed:17

LOCALIZAÇÃO

Basolateral cell membraneBasal cell membrane

VIAS BIOLÓGICAS (4)
Heme degradationAtorvastatin ADMERecycling of bile acids and saltsOrganic anion transport by SLCO transporters
MECANISMO DE DOENÇA

Hyperbilirubinemia, Rotor type

An autosomal recessive form of primary conjugated hyperbilirubinemia. Affected individuals develop mild jaundice not associated with hemolysis shortly after birth or in childhood. They have delayed plasma clearance of the unconjugated anionic dye bromsulphthalein and prominent urinary excretion of coproporphyrin I. Hepatic pigmentation is normal.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
41.3 TPM
Nervo tibial
2.6 TPM
Testículo
1.4 TPM
Glândula salivar
0.7 TPM
Cervix Endocervix
0.6 TPM
OUTRAS DOENÇAS (1)
Rotor syndrome
HGNC:10961UniProt:Q9NPD5
TJP2Tight junction protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in tight junctions and adherens junctions (By similarity). Acts as a positive regulator of RANKL-induced osteoclast differentiation, potentially via mediating downstream transcriptional activity (By similarity)

LOCALIZAÇÃO

Cell junction, adherens junctionCell membraneCell junction, tight junctionNucleus

VIAS BIOLÓGICAS (1)
Signaling by Hippo
MECANISMO DE DOENÇA

Hypercholanemia, familial, 1

A disorder characterized by elevated serum bile acid concentrations, itching, and fat malabsorption.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
103.6 TPM
Nervo tibial
85.5 TPM
Pulmão
84.2 TPM
Tecido adiposo
81.3 TPM
Tireoide
80.0 TPM
OUTRAS DOENÇAS (3)
cholestasis, progressive familial intrahepatic, 4hypercholanemia, familial 1autosomal dominant nonsyndromic hearing loss
HGNC:11828UniProt:Q9UDY2
SEMA7ASemaphorin-7ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Plays an important role in integrin-mediated signaling and functions both in regulating cell migration and immune responses. Promotes formation of focal adhesion complexes, activation of the protein kinase PTK2/FAK1 and subsequent phosphorylation of MAPK1 and MAPK3. Promotes production of pro-inflammatory cytokines by monocytes and macrophages. Plays an important role in modulating inflammation and T-cell-mediated immune responses. Promotes axon growth in the embryonic olfactory bulb. Promotes a

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Other semaphorin interactions
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 11

An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
236.5 TPM
Baço
90.0 TPM
Brain Spinal cord cervical c-1
67.1 TPM
Cerebelo
58.8 TPM
Testículo
57.1 TPM
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 11
HGNC:HGNC:10741UniProt:O75326
SLC51AOrganic solute transporter subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood (PubMed:16317684). Efficiently transports the major species of bile acids (taurocholate) (PubMed:16317684). Taurine conjugates are transported more efficiently across the basolateral membrane than glycine-conjugated bile acids (By similarity). Can also transport steroids such as estrone 3-sulfate and dehydroep

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Recycling of bile acids and salts
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 6

An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. PFIC6 patients have elevated liver transaminases and congenital diarrhea.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
18.9 TPM
Intestino delgado
17.6 TPM
Testículo
9.8 TPM
Glândula adrenal
5.3 TPM
Sangue
4.3 TPM
OUTRAS DOENÇAS (1)
cholestasis, progressive familial intrahepatic, 6
HGNC:HGNC:29955UniProt:Q86UW1
ATP8B1Phospholipid-transporting ATPase ICDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of phospholipids, in particular phosphatidylcholines (PC), from the outer to the inner leaflet of the plasma membrane (PubMed:17948906, PubMed:25315773). May participate in the establishment of the canalicular membrane integrity by ensuring asymmetric distribution of phospholipids in the canicular membrane (By similarity). Thus may have a role in the regulation of bile acids transpo

LOCALIZAÇÃO

Cell membraneApical cell membraneCell projection, stereociliumEndoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (1)
Ion transport by P-type ATPases
MECANISMO DE DOENÇA

Cholestasis, progressive familial intrahepatic, 1

A disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease before adulthood. PFIC1 inheritance is autosomal recessive.

OUTRAS DOENÇAS (4)
cholestasis, intrahepatic, of pregnancy, 1progressive familial intrahepatic cholestasis type 1benign recurrent intrahepatic cholestasis type 1intrahepatic cholestasis of pregnancy
HGNC:3706UniProt:O43520

Medicamentos e terapias

ODEVIXIBATPhase 3

Mecanismo: Ileal bile acid transporter inhibitor

MARALIXIBATPhase 3

Mecanismo: Ileal bile acid transporter inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

149 variantes patogênicas registradas no ClinVar.

🧬 USP53: NM_001371395.1(USP53):c.209del (p.Gly70fs) ()
🧬 USP53: NM_001371395.1(USP53):c.941G>A (p.Trp314Ter) ()
🧬 USP53: Single allele ()
🧬 USP53: NM_001371395.1(USP53):c.431G>A (p.Cys144Tyr) ()
🧬 USP53: NM_001371395.1(USP53):c.136G>T (p.Ala46Ser) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 0 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Alteração do metabolismo e excreção de bilirrubina

Centros de Referência SUS

21 centros habilitados pelo SUS para Alteração do metabolismo e excreção de bilirrubina

Centros para Alteração do metabolismo e excreção de bilirrubina

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
0 papers (10 anos)
#1

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology2026 Mar

Intravascular hemolysis accompanies diverse diseases, yet blood-based markers (eg, plasma-free hemoglobin [PFH], haptoglobin, lactate dehydrogenase [LDH], and bilirubin) are variably sensitive, nonspecific, or impractical for point-of-care use. We evaluated urinary carbonic anhydrase 1 (CA1) as a mechanistically grounded, urine-based marker of hemolysis in a multicenter study spanning the United Kingdom, Bangladesh, and Peru. We enrolled 234 participants: healthy adults and adults with inherited anemias (Oxford), newborns in intensive care (London), children and adults with complicated or uncomplicated malaria (Bangladesh), and adults attending rural clinics for various medical reasons (Peru). Urine CA1 and hemoglobin (Hb) were quantified by enzyme-linked immunosorbent assay and immunoblot, with CA1:Hb stoichiometry used to distinguish intravascular hemolysis from urogenital blood contamination. Relationships with PFH, LDH, bilirubin, Hb, C-reactive protein (CRP), and clinical variables were tested using regression, principal component analysis, and decision tree. Reference urine samples were predominantly CA1-negative/Hb-negative. In inherited anemias, urinary CA1 was highest in sickle cell disease and correlated with serum LDH and inversely with blood Hb. In neonates, longitudinal CA1 trajectories stratified infants into physiological, transient, and sustained hemolysis groups; higher CA1 levels were associated with prematurity, elevated CRP and lower white blood cell count. Urinary CA1 was detected in Bangladeshi patients with elevated PFH and in cases of intravascular hemolysis not identified by PFH. Among Peruvian participants, urinary CA1 correlated with raised CRP level, consistent with inflammation being a prohemolytic trigger. To enable rapid and cost-effective testing, a lateral flow device was developed and verified for excellent sensitivity and specificity. Urinary CA1 provides a sensitive and practical readout of intravascular hemolysis suitable for point-of-care testing globally.

#2

A novel pathogenic variant for dubin-johnson syndrome in a case of hyperbilirubinemia and metabolic associated fatty liver disease.

Scandinavian journal of gastroenterology2026 Feb 02

Dubin-Johnson Syndrome (DJS; OMIM 237500) is a rare autosomal recessive disorder caused by pathogenic variants in the ABCC2 gene, encoding for the multidrug resistance protein 2 (MRP2), resulting in impeded biliary excretion of bilirubin metabolites. It is typically characterized by chronic or intermittent jaundice and conjugated hyperbilirubinemia. We report the case of a 54-year-old male with hyperbilirubinemia (mostly conjugated) and hypertransaminasemia. Hypertransaminasemia was due to presence of Metabolic dysfunction-associated fatty liver disease (MASLD), while whole-genome sequencing revealed a homozygous missense variant affecting ABCC2 (c.3893G > A, p.Gly1298Asp), a previously undescribed variant likely linked to hyperbilirubinemia. It is an extremely rare genetic variant (allele frequency = 6.2 × 10-7). In silico analyses predicted the variant to be highly pathogenic (CADD score 29; AlphaMissense score 0.978; PhyloP 8.87; DynaMut ΔΔG = -0.765 kcal·mol-1 and ΔΔSVib = -0.234 kcal·mol-1·K-1). Structural modeling suggested no gross conformational changes but potential effects local conformation and overall function of the protein. We describe a novel ABCC2 mutation associated with Dubin-Johnson Syndrome. This finding expands the spectrum of ABCC2 variants to evaluate in case of hyperbilirubinemia and highlights the importance of genetic testing in unexplained cases of conjugated hyperbilirubinemia.

#3

Bioactive Metabolites from Lactobacillus acidophilus-Fermented Products Mitigate Carbon Tetrachloride-Induced Liver Injury: Biochemical and In Silico Insights.

Current developments in nutrition2026 Feb

Fermented products derived from Lactobacillus have demonstrated therapeutic potential in the management of metabolic disorders, particularly liver diseases. This study aimed to evaluate the hepatoprotective effects of Lactobacillus-fermented products in a carbon tetrachloride (CCl4)-induced murine model of liver damage, with a focus on analyzing the influence of bioactive compounds on key liver function biomarkers. Two Lactobacillus strains (Lactobacillus acidophilus LB-CARS1 and L. acidophilus ST-CARS2) were isolated from commercial yogurts, and milk was fermented using each strain. A total of 40 male Swiss Albino mice were allocated into 5 experimental groups: control, CCl4-only, CCl4 + silymarin, and 2 treatment groups receiving CCl4 plus 1 of the 2 lactic acid bacteria (LAB)-fermented products. After 6 wk, serum concentrations of aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), bilirubin, and creatinine were measured. A protein-protein network was constructed using the proteins responsible for hepatoprotection. The cellular pathways of these proteins were also visualized by the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Molecular docking was performed to assess interactions between identified bioactive compounds and target proteins (superoxide dismutase, catalase, transforming growth factor-β 1, peroxisome proliferator-activated receptor γ, IL-6, and tumor necrosis factor-α). Treatment with LAB-fermented products significantly reduced (P < 0.05) serum AST, ALT, ALP, bilirubin, and creatinine concentrations in the CCl4-treated mice. The 2 products reduced the liver enzymes, though their intensity was different. The interactive pathways of the protein network revealed the most common genes responsible for hepatoprotective activity. Molecular docking revealed strong binding affinities between bioactive compounds and proteins related to inflammation and oxidation. Furthermore, absorption, distribution, metabolism, excretion, and toxicity analysis suggested the potential drug candidates among the docked compounds. The results indicate that LAB-fermented products contain bioactive compounds capable of attenuating liver injury, likely through anti-inflammatory and antioxidant mechanisms, highlighting their potential as functional food interventions in hepatoprotection.

#4

Clinical and Demographic Profile of Wilson Disease in Young Adults: A Retrospective Study at a Tertiary Care Center in Peshawar, Pakistan.

Cureus2026 Jan

Background Wilson disease (WD) is a rare autosomal recessive disorder of copper metabolism and an important treatable cause of hepatic dysfunction in young adults. Data from South Asian populations remains limited. Hence, the current study aimed to assess the demographic characteristics, clinical features, and diagnostic profile of patients with WD presenting at a tertiary care hospital in Peshawar, Pakistan. Methods This retrospective descriptive study was conducted in the Department of Medicine, Hayatabad Medical Complex, Peshawar, between January 2023 and December 2024. Medical records were systematically reviewed to identify all patients diagnosed with WD during this period. 21 patients with a confirmed WD diagnosis based on the modified Leipzig scoring system (score ≥ 4) and complete diagnostic workup were included. Complete diagnostic data was defined as documented serum ceruloplasmin, 24-hour urinary copper excretion, liver function tests, slit-lamp examination for Kayser-Fleischer (KF) rings, and negative screening for viral and autoimmune hepatitis. Demographic, clinical, and biochemical data were extracted from hospital records and analyzed using SPSS version 25. Post-hoc ethical approval was obtained from the institutional review board. Results The mean age at presentation was 23.2 ± 4.8 years (range 18-35), with a male-to-female ratio of 2:1. 15 patients (71.4%) were between 18 and 25 years of age. Jaundice was the predominant symptom, observed in 21 (100%) patients, while hepatomegaly and KF rings were observed in 18 (85.7%) and 12 (57.1%) of patients, respectively. The mean 24-hour urinary copper excretion was 1,450.3 ± 420.7 µg/day, and the mean serum ceruloplasmin level was 8.4 ± 3.2 mg/dL. Four patients (19%) were from two consanguineous families. A positive correlation between urinary copper and total bilirubin levels was observed (r = 0.74, p < 0.001). Conclusion WD in this internal medicine cohort primarily affected young adults presenting with hepatic manifestations, most commonly jaundice. Elevated urinary copper excretion and reduced serum ceruloplasmin levels were consistent diagnostic findings. Familial clustering, particularly in consanguineous families, was also observed, indicating a pattern consistent with autosomal recessive inheritance within this population.

#5

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data.

CPT: pharmacometrics &amp; systems pharmacology2026 Feb

Bilirubin is a breakdown product of erythrocytes and plays a crucial role in elimination of heme-containing proteins. After its synthesis in the reticuloendothelial system, unconjugated bilirubin is released into plasma and taken up into the liver. In hepatocytes, bilirubin is conjugated and excreted into the gastrointestinal tract via bile, where it is further converted to urobilinoids. There are various genetic factors causing abnormal bilirubin levels in plasma, such as Gilbert syndrome, Crigler-Najjar syndrome, Dubin-Johnson syndrome, and Rotor syndrome. To better understand bilirubin metabolism and its disorders, this study develops a physiologically based computational model incorporating published literature as well as real-world clinical data from the Explorys database. The model simulates bilirubin levels in both healthy individuals and patients with disorders of bilirubin metabolism. Population simulations show that Gilbert syndrome requires a substantial reduction in UDP-glucuronosyltransferase 1A1 activity, while Crigler-Najjar syndrome requires near-complete loss of its function. In contrast, Dubin-Johnson syndrome is characterized by a significant impairment of multidrug resistance-associated protein 2 activity. To also illustrate model behavior under targeted perturbations, we simulated administration of atazanavir in healthy individuals and patients with Gilbert syndrome to investigate its effect on bilirubin levels. Relative to baseline, unconjugated bilirubin maximum concentration (Cmax) increased by 34% in healthy individuals but by 67% in Gilbert syndrome. Overall, this study provides a conceptual and mechanistically informed framework for studying bilirubin homeostasis and the functional consequences of drug administration in health and disease.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 83

2026

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology
2026

Bioactive Metabolites from Lactobacillus acidophilus-Fermented Products Mitigate Carbon Tetrachloride-Induced Liver Injury: Biochemical and In Silico Insights.

Current developments in nutrition
2026

Clinical and Demographic Profile of Wilson Disease in Young Adults: A Retrospective Study at a Tertiary Care Center in Peshawar, Pakistan.

Cureus
2026

A novel pathogenic variant for dubin-johnson syndrome in a case of hyperbilirubinemia and metabolic associated fatty liver disease.

Scandinavian journal of gastroenterology
2026

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data.

CPT: pharmacometrics &amp; systems pharmacology
2025

Staged approach to overcome hyperbilirubinemia: tailored chemotherapy in liver metastases-a case report.

Journal of gastrointestinal oncology
2025

LC-MS-Based Untargeted Metabolic Profiling in Plasma Following Dapagliflozin Administration in Healthy Volunteers.

Metabolites
2025

OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria.

Drug metabolism and disposition: the biological fate of chemicals
2025

Bilirubin metabolism and its application in disease prevention: mechanisms and research advances.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2025

Yinchenhao decoction alleviates obstructive jaundice liver injury by modulating epidermal growth factor receptor and constitutive androstane receptor signaling.

World journal of hepatology
2025

Chemotherapy-Induced Unconjugated Hyperbilirubinemia Complicated by Other Trigger Factors in a Child with T-Cell Acute Lymphoblastic Leukaemia and UGT1A1 Mutation-Associated Gilbert Syndrome.

Current oncology (Toronto, Ont.)
2025

Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome.

Metabolism: clinical and experimental
2024

Arachidonic acid enhances hepatocyte bile acid uptake and alleviates cholestatic liver disease by upregulating OATP1 expression.

Food &amp; function
2024

Relapse following withdrawal of D-penicillamine from combination (D-penicillamine + zinc) therapy in hepatic Wilson disease.

Journal of pediatric gastroenterology and nutrition
2024

Comparison of the efficacy of the gadoxetic acid MRI-derived relative enhancement index (REI) and functional liver imaging score (FLIS) in predicting liver function: validation with Albumin-Bilirubin (ALBI) grade.

Abdominal radiology (New York)
2024

Transport mechanism of human bilirubin transporter ABCC2 tuned by the inter-module regulatory domain.

Nature communications
2023

Is Environmental Cadmium Exposure Causally Related to Diabetes and Obesity?

Cells
2024

The Effect of Probiotics on Phototherapy for Bilirubin Reduction in Term Neonates: A Randomized Controlled Trial.

Current pediatric reviews
2023

Aryl hydrocarbon receptor attenuates cholestatic liver injury by regulating bile acid metabolism.

Biochemical and biophysical research communications
2023

Evaluating variations in bilirubin glucuronidation activity by protease inhibitors in canine and human primary hepatocytes cultured in a 3D culture system.

Toxicology in vitro : an international journal published in association with BIBRA
2023

Continuous exposure to bisphenol S increases the accumulation of endogenous metabolic toxicants by obstructing the glucuronic acid pathway.

Environmental pollution (Barking, Essex : 1987)
2023

Gallic acid improves liver cirrhosis by reducing oxidative stress and fibrogenesis in the liver of rats induced by bile duct ligation.

Scandinavian journal of gastroenterology
2023

Biochemical and Hematological Indexes of Liver Dysfunction in Horses.

Journal of equine veterinary science
2023

Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin.

Acta pharmaceutica Sinica. B
2022

Mechanism of crocin I on ANIT-induced intrahepatic cholestasis by combined metabolomics and transcriptomics.

Frontiers in pharmacology
2022

A Case of Megaspleen With Micrographism.

Cureus
2022

Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.

JHEP reports : innovation in hepatology
2022

The mechanism of Yinchenhao decoction in treating obstructive-jaundice-induced liver injury based on Nrf2 signaling pathway.

World journal of gastroenterology
2022

Rotor Syndrome Presenting as Dubin-Johnson Syndrome.

Case reports in gastroenterology
2022

Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review.

United European gastroenterology journal
2022

Sexual dimorphism: increased sterol excretion leads to hypocholesterolaemia in female hyperbilirubinaemic Gunn rats.

The Journal of physiology
2022

4-Phenylbutyrate protects against rifampin-induced liver injury via regulating MRP2 ubiquitination through inhibiting endoplasmic reticulum stress.

Bioengineered
2021

UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers.

Xenobiotica; the fate of foreign compounds in biological systems
2021

Mechanism of bilirubin elimination in urine: insights and prospects for neonatal jaundice.

Clinical chemistry and laboratory medicine
2021

Dubin-Johnson Syndrome as Differential Diagnosis for Neonatal Cholestasis.

Journal of pediatric gastroenterology and nutrition
2020

[Evaluating the efficacy of diet therapy with protein component modification at Wilson disease].

Voprosy pitaniia
2020

How Patients With Chronic Liver Diseases Succeed to Deal With COVID-19?

Frontiers in medicine
2020

Immune Checkpoint Inhibitor-induced Fanconi Syndrome.

Cureus
2020

Induction of Steatohepatitis and Liver Tumorigenesis by Enforced Snail Expression in Hepatocytes.

The American journal of pathology
2020

Temporal profile of HEV RNA concentration in blood and stool from patients with acute uncomplicated hepatitis E in a region with genotype 1 predominance.

Journal of viral hepatitis
2019

Non-urate transporter 1, non-glucose transporter member 9-related renal hypouricemia and acute renal failure accompanied by hyperbilirubinemia after anaerobic exercise: a case report.

BMC nephrology
2019

Yellow fever: profile of cases and factors associated with death in a hospital in the State of Rio de Janeiro, 2017-2018.

Revista de saude publica
2020

Cholemic Nephropathy Reloaded.

Seminars in liver disease
2019

Arterial Blood Pressure at Liver Transplant Evaluation Predicts Renal Histology in Candidates With Renal Dysfunction.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2019

Nineteenth-Century Homeopathic Repertories Predict Increased Urinary Excretion of Bile in Cholestasis but Not in Non-Cholestatic Infant Jaundice.

Homeopathy : the journal of the Faculty of Homeopathy
2019

Plants used for the treatment of icterus (jaundice) in Central India: A review.

Annals of hepatology
2019

Body distribution of stable copper isotopes during the progression of cholestatic liver disease induced by common bile duct ligation in mice.

Metallomics : integrated biometal science
2019

Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice.

Journal of hepatology
2019

Unconjugated bilirubin and schizophrenia: a systematic review.

CNS spectrums
2019

Heme oxygenase-1 induction by hemin prevents oxidative stress-induced acute cholestasis in the rat.

Clinical science (London, England : 1979)
2018

Neonatal Cholestasis: A Primer of Selected Etiologies.

Pediatric annals
2018

Meconium microbiome associates with the development of neonatal jaundice.

Clinical and translational gastroenterology
2019

Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.

Journal of internal medicine
2018

Association of serum zinc with markers of liver injury in very heavy drinking alcohol-dependent patients.

The Journal of nutritional biochemistry
2018

Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Experimental and therapeutic medicine
2018

Bilirubin in the Liver-Gut Signaling Axis.

Trends in endocrinology and metabolism: TEM
2018

Toxicity and toxicokinetics of Amanita exitialis in beagle dogs.

Toxicon : official journal of the International Society on Toxinology
2017

[The diagnostic value and limits of diagnostic parameters for Wilson's disease].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2018

Inhibition of UDP-glucose dehydrogenase by 6-thiopurine and its oxidative metabolites: Possible mechanism for its interaction within the bilirubin excretion pathway and 6TP associated liver toxicity.

Journal of pharmaceutical and biomedical analysis
2018

The UGT1A1*28 gene variant predicts long-term mortality in patients undergoing coronary angiography.

Clinical chemistry and laboratory medicine
2017

Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.

The lancet. Gastroenterology &amp; hepatology
2017

p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.

British journal of pharmacology
2017

Role of Hepatobiliary Scintigraphy and Preoperative Liver Biopsy for Exclusion of Biliary Atresia in Neonatal Cholestasis Syndrome.

Indian journal of pediatrics
2018

Serum bilirubin levels are negatively associated with diabetic retinopathy in patients with type 1 diabetes and normal renal function.

International ophthalmology
2017

Diagnosis and evaluation of hyperbilirubinemia.

Current opinion in gastroenterology
2017

Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.

Clinical pharmacology in drug development
2017

The role of Ntcp, Oatp2, Bsep and Mrp2 in liver injury induced by Dioscorea bulbifera L. and Diosbulbin B in mice.

Environmental toxicology and pharmacology
2017

Gunn Rats as a Surrogate Model for Evaluation of Hepatocyte Transplantation-Based Therapies of Crigler-Najjar Syndrome Type 1.

Methods in molecular biology (Clifton, N.J.)
2016

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Annals of hematology
2016

Cholic acid therapy in Zellweger spectrum disorders.

Journal of inherited metabolic disease
2016

Choledochojejunostomy with an innovative magnetic compressive anastomosis: How to determine optimal pressure?

World journal of gastroenterology
2016

Inherited disorders of bilirubin clearance.

Pediatric research
2017

Coronary Artery Disease in Patients With Disorders of Bilirubin Excretion.

American journal of therapeutics
2015

Biliverdin Reductase A (BVRA) Mediates Macrophage Expression of Interleukin-10 in Injured Kidney.

International journal of molecular sciences
2015

Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease.

Parkinsonism &amp; related disorders
2016

Genetic and biochemical study of dual hereditary jaundice: Dubin-Johnson and Gilbert's syndromes. Haplotyping and founder effect of deletion in ABCC2.

European journal of human genetics : EJHG
2016

Polarized release of hepatic microRNAs into bile and serum in response to cellular injury and impaired liver function.

Liver international : official journal of the International Association for the Study of the Liver
2015

Expression of renal Oat5 and NaDC1 transporters in rats with acute biliary obstruction.

World journal of gastroenterology
2015

Serum bilirubin concentration is associated with eGFR and urinary albumin excretion in patients with type 1 diabetes mellitus.

Journal of diabetes and its complications
2015

Bile cast nephropathy due to cholestatic jaundice after using stanozolol in 2 amateur bodybuilders.

Iranian journal of kidney diseases
2016

Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

Hepatology (Baltimore, Md.)
2015

D-Galactosamine Intoxication in Experimental Animals: Is it Only an Experimental Model of Acute Liver Failure?

Medical science monitor : international medical journal of experimental and clinical research
2015

Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis.

Journal of visualized experiments : JoVE

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Alteração do metabolismo e excreção de bilirrubina.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Alteração do metabolismo e excreção de bilirrubina

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.
    Blood global hematology· 2026· PMID 41737922mais citado
  2. A novel pathogenic variant for dubin-johnson syndrome in a case of hyperbilirubinemia and metabolic associated fatty liver disease.
    Scandinavian journal of gastroenterology· 2026· PMID 41622857mais citado
  3. Bioactive Metabolites from Lactobacillus acidophilus-Fermented Products Mitigate Carbon Tetrachloride-Induced Liver Injury: Biochemical and In Silico Insights.
    Current developments in nutrition· 2026· PMID 41732743mais citado
  4. Clinical and Demographic Profile of Wilson Disease in Young Adults: A Retrospective Study at a Tertiary Care Center in Peshawar, Pakistan.
    Cureus· 2026· PMID 41635375mais citado
  5. Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data.
    CPT: pharmacometrics &amp; systems pharmacology· 2026· PMID 41543361mais citado
  6. Incidental Scleral Icterus in an Adolescent Male With Nausea: Clinical Diagnosis of Gilbert Syndrome in the Pediatric Outpatient Setting.
    Cureus· 2023· PMID 37692716recente
  7. Jaundice.
    Am Fam Physician· 1992· PMID 1543099recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:309816(Orphanet)
  2. MONDO:0017755(MONDO)
  3. GARD:21347(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787331(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Alteração do metabolismo e excreção de bilirrubina
Compêndio · Raras BR

Alteração do metabolismo e excreção de bilirrubina

ORPHA:309816 · MONDO:0017755
CID-11
Medicamentos
2 registrados
MedGen
UMLS
C0349427
Wikidata
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades